



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – October 2, 2018

MEDraysintell to Showcase its Reports at EANM in Düsseldorf

MEDraysintell will display its series of market reports and directories with over 2,200 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the EANM – European Association of Nuclear Medicine – congress (Düsseldorf, Germany, October 13-17, 2017). <https://eanm18.eanm.org/>.

If you are looking for the ultimate reference resource in Nuclear Medicine, written by experts, **Come and see us on The Belgian Pavilion booth-14.**

The global market for nuclear medicine is expected to reach up to US\$ 26 billion in 2030, from US\$ 4.8 billion in 2017, a realistic figure that seems to be confirmed by major recent changes and investments in this area. The strong growth of radiotherapeutics which represented 13% of the total nuclear medicine market in 2017, compared to 4% in 2013, will represent more than 60% of the US\$ 26 billion nuclear medicine market by 2030.

On an optimistic basis, figures for 2030 could even be higher as they are not taking in account the new therapeutic approaches that have been initiated over the past twelve months, and we prefer to wait confirmation of all these new investments before integrating in these figures their chances of success.

A growing number of companies, often start-ups, are developing radiopharmaceuticals on this basis and will soon need to link with larger partners and/or investors.

All these topics and much more are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2018. The MEDraysintell Nuclear Medicine report has become the sole trusted source of intelligence in this industry and this fifth edition will prove once again to be the best advising tool for the pharmaceutical and radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A) in this field.

MEDraysintell reports and directories are becoming the sole trusted sources of intelligence in the radiation healthcare industry. Reports can be customized to specific areas or modalities. Sample pages and complete table of contents are available upon request. MEDraysintell also welcomes your requests for specific intelligence needs in these areas.

We look forward to seeing you in Düsseldorf!

About MEDraysintell

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,200 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 70 years of experience in radiation healthcare. www.medraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@medraysintell.com
Mobile: +33 6 82 80 06 00